|
Hepatitis B, Chronic
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Controversies exist regarding the classification of the different clinical phases of chronic hepatitis B (CHB) because hepatitis B virus (HBV) DNA and alanine aminotransferase levels fluctuate over time.<sup>1,2</sup> To improve the distinction of clinical phases and the associated spectrum of clinical outcome,<sup>3,4</sup> hepatitis B surface antigen (HBsAg) levels may be of help.<sup>5-7</sup> We hypothesize that HBV genotype specific HBsAg levels are needed for the identification of different clinical HBV disease phases.<sup>7</sup>.
|
30630104 |
2020 |
|
Hepatitis B, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
It is still vague for chronic hepatitis B (CHB) patients with normal or mildly increasing alanine aminotransferase (ALT) level to undergo antiviral treatment or not.
|
30937309 |
2019 |
|
Hepatitis B, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Little is known about cause and intervention for alanine aminotransferase (ALT) elevation after complete viral suppression in patients with chronic hepatitis B (CHB).
|
31370059 |
2019 |
|
Hepatitis B, Chronic
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Alterations of the Gut Microbiome in Chronic Hepatitis B Virus Infection Associated with Alanine Aminotransferase Level.
|
30717396 |
2019 |
|
Hepatitis B, Chronic
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
It remains unknown whether antiviral treatment for HBeAg-negative chronic hepatitis B (CHB) patients having high viral loads without significant elevation of alanine aminotransferase (ALT) levels would reduce the risks of clinical events.
|
31135074 |
2019 |
|
Hepatitis B, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Clinical noninvasive markers for antiviral therapy decision in chronic hepatitis B with alanine aminotransferase less than two times upper limit of normal.
|
30380162 |
2019 |
|
Hepatitis B, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
To determine and validate alanine aminotransferase (ALT)-adapted dual cut-offs of liver stiffness measurements (LSMs) for assessing liver fibrosis with two-dimensional shear wave elastography (2D-SWE) in patients with chronic hepatitis B (CHB) infection.
|
30039224 |
2019 |
|
Hepatitis B, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Total Alanine Aminotransferase (ALT) Flares in Pregnant North American Women With Chronic Hepatitis B Infection: Results From a Prospective Observational Study.
|
31082876 |
2019 |
|
Hepatitis B, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Baseline HBsAg levels associated with HBsAg loss in HBeAg-negative chronic hepatitis B infection with persistently normal alanine aminotransferase.
|
30528063 |
2019 |
|
Hepatitis B, Chronic
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Abnormal IL-10 levels were related to alanine aminotransferase abnormalities during postpartum in HBeAg positive women with chronic hepatitis B.
|
31725660 |
2019 |
|
Hepatitis B, Chronic
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Accurate detection of significant fibrosis (fibrosis stage 2 or higher on the METAVIR scale) is important especially for chronic hepatitis B (CHB) patients with high viral loads but with normal or mildly elevated alanine aminotransferase (ALT) levels because the presence of significant fibrosis is accepted as the indication for antiviral treatment.
|
31333316 |
2019 |
|
Hepatitis B, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study was performed to assess the predictive value of spleen thickness for liver pathology and the role of routine follow-up procedures in significant liver pathology for patients with chronic hepatitis B (CHB) with persistently normal alanine aminotransferase (PNALT) or minimally raised alanine aminotransferase (ALT).
|
30213226 |
2019 |
|
Hepatitis B, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
We evaluated liver fibrosis in patients with chronic hepatitis B (CHB) and mildly raised alanine transaminase (ALT) activities between 1-2 times the upper limit of normal (ULN) which was near the threshold for initiating treatment.
|
30471249 |
2019 |
|
Hepatitis B, Chronic
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Chronic hepatitis B (CHB) patients with normal alanine aminotransferase (ALT) levels are not free from significant hepatic lesions.
|
28707778 |
2018 |
|
Hepatitis B, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Declining diagnostic accuracy of non-invasive fibrosis tests is associated with elevated alanine aminotransferase in chronic hepatitis B.
|
30397608 |
2018 |
|
Hepatitis B, Chronic
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Serum alanine aminotransferase level and liver-related mortality in patients with chronic hepatitis B: A large national cohort study.
|
29377574 |
2018 |
|
Hepatitis B, Chronic
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Liver biopsy was performed on high level of HBV DNA of 455 patients with HBsAg-positive and HBeAg-positive chronic hepatitis B infection and persistently normal alanine aminotransferase level.
|
30180183 |
2018 |
|
Hepatitis B, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study aimed to explore whether plasma miRNAs may serve as new biomarkers for liver injury among chronic hepatitis B (CHB) patients with normal or nearly normal alanine aminotransferase (ALT) levels.
|
29881991 |
2018 |
|
Hepatitis B, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
We aimed to evaluate the impact of normal on-treatment ALT during antiviral treatment with entecavir (ETV) or tenofovir disoproxil fumarate (TDF) in patients with chronic hepatitis B (CHB).
|
29758335 |
2018 |
|
Hepatitis B, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Predictors for advanced liver fibrosis in chronic hepatitis B virus infection with persistently normal or mildly elevated alanine aminotransferase.
|
29285064 |
2017 |
|
Hepatitis B, Chronic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We aimed to evaluate the diagnostic value of serum hepatitis B surface antigen (HBsAg) levels for liver fibrosis in hepatitis B e antigen-positive [HBeAg (+)] chronic hepatitis B (CHB) patients with alanine transaminase (ALT)≤twice upper limit of normal (ULN).
|
29156808 |
2017 |
|
Hepatitis B, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Non-ALT biomarkers for markedly abnormal liver histology among Chinese persistently normal alanine aminotransferase-chronic hepatitis B patients.
|
28487618 |
2017 |
|
Hepatitis B, Chronic
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Despite complete suppression of viral DNA with antiviral agents, in some patients with chronic hepatitis B (CHB), serum levels of alanine aminotransferase (ALT) do not normalize.
|
28215615 |
2017 |
|
Hepatitis B, Chronic
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
TDF was more effective than the placebo in reducing vertical transmission in HBeAg-positive chronic hepatitis B (CHB) pregnancies with high serum HBV-DNA levels (OR = 0.21, 95% CI = 0.07-0.61) at 4-12 months, infant HBV DNA seropositivity at delivery (OR = 0.16, 95% CI = 0.07-0.37), and a severe flair in maternal alanine aminotransferase (ALT) levels (OR = 0.43, 95% CI = 0.19-0.95) during pregnancy.
|
28646142 |
2017 |
|
Hepatitis B, Chronic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In chronic hepatitis B (CHB) carriers, alanine transaminase (ALT) flares are common in the peripartum period.
|
28544232 |
2017 |